- Home
- VCEL vs ELVN Comparison
VCEL vs ELVN Comparison
Compare VCEL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VCEL | ELVN |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VCEL | ELVN |
|---|---|---|
| Price | $33.42 | $29.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $58.50 | $41.00 |
| AVG Volume (30 Days) | 423.1K | ★ 573.1K |
| Earning Date | 05-18-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | 3.17 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $276,259,000.00 | N/A |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $17.96 | $40.06 |
| P/E Ratio | $105.00 | ★ N/A |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $29.24 | $13.30 |
| 52 Week High | $49.10 | $30.63 |
Technical Indicators
Market Signals| Indicator | VCEL | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 61.50 |
| Support Level | $29.59 | $18.41 |
| Resistance Level | $38.48 | $29.63 |
| Average True Range (ATR) | 1.57 | 1.48 |
| MACD | -0.34 | -0.01 |
| Stochastic Oscillator | 10.53 | 80.02 |
Price Performance
Historical ComparisonAbout VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.